MA33387B1 - Polypeptides et procede de traitement - Google Patents

Polypeptides et procede de traitement

Info

Publication number
MA33387B1
MA33387B1 MA34497A MA34497A MA33387B1 MA 33387 B1 MA33387 B1 MA 33387B1 MA 34497 A MA34497 A MA 34497A MA 34497 A MA34497 A MA 34497A MA 33387 B1 MA33387 B1 MA 33387B1
Authority
MA
Morocco
Prior art keywords
antigen
polypeptides
processing method
binding
present
Prior art date
Application number
MA34497A
Other languages
Arabic (ar)
English (en)
Inventor
Michael Neil Burden
Paul Andrew Hamblin
Jonathan David Larkin
John Richard White
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA33387B1 publication Critical patent/MA33387B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

L'invention concerne une protéine de liaison à l'antigène isolée qui comprend au moins un premier domaine variable d'immunoglobuline capable de se lier à l'ADAMTS5 humain. L'invention concerne également des protéines de liaison à l'antigène selon la présente invention qui sont des anticorps monoclonaux, des compositions pharmaceutiques comprenant lesdites protéines de liaison à l'antigène et des procédés de traitement.
MA34497A 2009-07-02 2010-07-01 Polypeptides et procede de traitement MA33387B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22252109P 2009-07-02 2009-07-02
US24975709P 2009-10-08 2009-10-08
PCT/US2010/040724 WO2011002968A2 (fr) 2009-07-02 2010-07-01 Polypeptides et procédé de traitement

Publications (1)

Publication Number Publication Date
MA33387B1 true MA33387B1 (fr) 2012-06-01

Family

ID=43411744

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34497A MA33387B1 (fr) 2009-07-02 2010-07-01 Polypeptides et procede de traitement

Country Status (21)

Country Link
US (1) US20120095193A1 (fr)
EP (1) EP2449127A4 (fr)
JP (1) JP2012531902A (fr)
KR (1) KR20120098587A (fr)
CN (1) CN102482700A (fr)
AR (1) AR077630A1 (fr)
AU (1) AU2010266272A1 (fr)
BR (1) BR112012000025A2 (fr)
CA (1) CA2766641A1 (fr)
CL (1) CL2011003354A1 (fr)
CO (1) CO6480976A2 (fr)
CR (1) CR20120027A (fr)
DO (1) DOP2011000404A (fr)
IL (1) IL217292A0 (fr)
MA (1) MA33387B1 (fr)
MX (1) MX2012000055A (fr)
PE (1) PE20120554A1 (fr)
SG (1) SG177288A1 (fr)
TW (1) TW201114436A (fr)
UY (1) UY32752A (fr)
WO (1) WO2011002968A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190112175A (ko) 2010-12-01 2019-10-02 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US20130336989A1 (en) * 2011-02-24 2013-12-19 Glaxo Group Limited Methods of identifying a patient population
WO2013109829A1 (fr) * 2012-01-20 2013-07-25 Glaxosmithkline Intellectual Property Development Ltd Anticorps anti-adamts4 et méthodes de traitement
PL2650310T3 (pl) 2012-04-13 2017-01-31 Rottapharm Biotech S.R.L. Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
SI3057992T1 (sl) * 2013-10-15 2024-09-30 Genefrontier Corporation Humano protitelo proti vrsti ADAMTS agrekanaznega tipa za terapevtike proti boleznim, ki so povezane z agrekanazo
WO2017019729A1 (fr) * 2015-07-27 2017-02-02 The General Hospital Corporation Dérivés d'anticorps présentant une fonction effectrice activée de manière conditionnelle
US11813307B2 (en) 2017-06-02 2023-11-14 Merck Patent Gmbh Polypeptides binding ADAMTS5, MMP13 and aggrecan
WO2018220235A1 (fr) * 2017-06-02 2018-12-06 Merck Patent Gmbh Immunoglobulines de liaison à mmp13
BR112019024333A2 (pt) * 2017-06-02 2020-07-28 Merck Patent Gmbh imunoglobulinas de ligação adamts
WO2018220225A1 (fr) * 2017-06-02 2018-12-06 Ablynx Nv Immunoglobulines liant l'aggrécane
EP3708666A4 (fr) * 2017-11-09 2021-07-21 Ribomic Inc Aptamer pour adamts5 et utilisation pour aptamer pour adamts5
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
WO2021154534A1 (fr) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Anticorps bispécifiques plap-cd3 epsilon
WO2024054922A1 (fr) * 2022-09-07 2024-03-14 Synoa Therapeutics, Llc Méthodes et compositions comprenant de nouveaux anticorps bispécifiques
CN119775410B (zh) * 2025-03-11 2025-04-29 成都大熊猫繁育研究基地 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
CA2548513A1 (fr) * 2003-12-04 2005-07-07 Wyeth Sulfonamides de biaryle et procedes d'utilisation

Also Published As

Publication number Publication date
UY32752A (es) 2011-01-31
AU2010266272A1 (en) 2012-01-19
PE20120554A1 (es) 2012-06-08
AR077630A1 (es) 2011-09-14
WO2011002968A2 (fr) 2011-01-06
MX2012000055A (es) 2012-01-27
EP2449127A2 (fr) 2012-05-09
KR20120098587A (ko) 2012-09-05
EP2449127A4 (fr) 2013-01-16
CR20120027A (es) 2012-05-16
DOP2011000404A (es) 2012-04-15
CA2766641A1 (fr) 2011-01-06
IL217292A0 (en) 2012-02-29
SG177288A1 (en) 2012-02-28
WO2011002968A3 (fr) 2011-04-07
TW201114436A (en) 2011-05-01
US20120095193A1 (en) 2012-04-19
CO6480976A2 (es) 2012-07-16
BR112012000025A2 (pt) 2015-09-08
CN102482700A (zh) 2012-05-30
JP2012531902A (ja) 2012-12-13
CL2011003354A1 (es) 2012-07-20

Similar Documents

Publication Publication Date Title
MA33387B1 (fr) Polypeptides et procede de traitement
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
SG196697A1 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
UA102667C2 (uk) Людське нейтралізуюче антитіло проти в7rp1
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA35208B1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
GEP20104922B (en) Antibodies to m-csf
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
UA130540C2 (uk) Композиція антитіла b7-h4
WO2019060750A3 (fr) Compositions d'anticorps a33 et leurs méthodes d'utilisation en radioimmunothérapie
MA38161A1 (fr) Anticorps anti-bmp-6
MA34742B1 (fr) Proteines de liaison à l'antigène
BR112022005410A2 (pt) Métodos e composições compreendendo um anticorpo monoclonal anti-ctla4 com proteínas de célula hospedeira reduzidas e estabilidade de polissorbato 80 aumentada
MA48241A1 (fr) Anticorps dirigés contre madcam